Trial Profile
Randomized Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line for HER2positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Previously Treated With Trastuzumab and Taxanes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Capecitabine; Vinorelbine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 25 Oct 2011 Planned End Date changed from 1 Dec 2007 to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 25 Oct 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 25 Oct 2011 PEC (therapeutic area) has been removed as reported by ClinicalTrials.gov.